Phase II clinical trials of mature B-cell neoplasms in children: A Japanese Cooperative Studies

Phase II clinical trials of mature B-cell neoplasms in children: A Japanese Cooperative Studies - Clinical trials of childhood B-cell lymphomas

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000317

Enrollment

308

Registered

2006-02-05

Start date

2005-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mature B-cell non-Hodgkin's lymphoa

Interventions

All registered patients are stratified into four risk groups(G1:stage I/II and resected tumors

G2:stage I/II and unresected tumors

G3:stage III/stage IV CNS negative

G4:stage IV CNS positive & Burkitt leukemia). Patients in G1 will receive two courses of A. Patients in G2 will receive two courses of A and B. Patients in G3 will receive four courses of A and two co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed patients with mature B-cell lymphomas including diffuse large B-cell lymphoma,mediastinal large B-cell lymphoma and Burkitt lymphoma/leukemia.

Exclusion criteria

Exclusion criteria: 1, Down's syndrome(21 trisomy) 2, Previous malignancy of any type 3, Prior stem cell/organ transplantation 4, Congenital immunodeficiency 5, HIV positivity

Design outcomes

Primary

Measure	Time frame
2 year event-free survival	—

Secondary

Measure	Time frame
(1) 2 year overall survival (2) incidence of therapy-related severe toxicity	—

Countries

Japan

Contacts

Public ContactSaito akiko

JPLSG data center

jplsgdata@nnh.hosp.go.jp052-951-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026